Breadcrumb

[G19-11] Cabozantinib (hepatocellular carcinoma) - Second Addendum to Commission A18-85

Overview

Overview

Commission: Commission awarded on 2019-04-24 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Health Economics
Current document:PDF Addendum to Commission A18-85  [PDF, 126 kB] (German version) Further documents
Note:

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.

Contact address:to the contact form
Linked projects: [A19-38] Cabozantinib (hepatocellular carcinoma) - Addendum to Commission A18-85
Status: Commission completed

[A18-85] Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-06-06 Addendum to Commission A18-85 (German version) 126 kBPDFdownload file

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2019-06-06 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close